Full-Time

Vice President

Translational Biology

Confirmed live in the last 24 hours

Orbital Therapeutics

Orbital Therapeutics

51-200 employees

Develops RNA-based medicines and therapies

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in immunology, genetics, bioengineering, or a related field.
  • Must have 12 years of postdoctoral experience as well as 7 years within biotechnology/pharmaceutical, including experience performing immunological research.
  • Broad scientific and technical expertise in immunology, particularly in autoimmune diseases and immune-oncology required.
  • Scientific and technical expertise in cell and gene therapy would be a plus.
  • Demonstrated strong ability to lead a team of experienced leaders required.
  • Experience with writing regulatory documents to support FIH studies required.
  • Takes accountability for actions and drives results.
  • Strong interpersonal and presentation skills with good judgment and ability to communicate with a diverse range of individuals.
Responsibilities
  • Work with the leadership team to provide strategy and vision and make decisions that establish objectives for the overall direction of Orbital’s research in line with company’s portfolio.
  • Innovate novel scientific projects/platforms for the company.
  • Develop essential methods for identifying clinical biomarkers and correlatives, including ensuring the appropriate collection, processing, and analysis of clinical samples.
  • Motivate and grow the research teams to achieve corporate objectives.
  • Oversee the development of preclinical IND packages for portfolio products, including nonclinical study reports and regulatory documents.
  • Work with the Clinical team to develop target candidate profiles and design experiments that support clinical plans.
  • Present experimental findings regularly to the leadership team and supervise the team members as they generate records, and present data.
  • Help draft progress reports and summaries for patent applications and/or scientific publications and provide external representation at conferences.

Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology along with advanced delivery methods and data science to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, which sets it apart in the RNA medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these medicines to healthcare providers who treat patients with various conditions.

Company Stage

Series A

Total Funding

$262.6M

Headquarters

San Francisco, California

Founded

2022

Growth & Insights
Headcount

6 month growth

13%

1 year growth

11%

2 year growth

235%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $270 million in Series A financing provides substantial capital to advance their RNA-based therapeutic platform.
  • The company's focus on next-generation vaccines, immunomodulation, and protein replacement positions it at the forefront of innovative treatments for various diseases.
  • Strategic partnerships, such as with Beam Therapeutics, enhance Orbital's capabilities in RNA and delivery technologies, broadening their therapeutic applications.

What critics are saying

  • The highly competitive field of RNA-based medicines requires continuous innovation to maintain a leading position.
  • The complexity of developing and commercializing RNA-based therapies could lead to longer timelines and higher costs.

What makes Orbital Therapeutics unique

  • Orbital Therapeutics focuses exclusively on RNA-based medicines, excluding small interfering RNA, which sets it apart from other genetic medicine companies.
  • The company leverages a unique combination of RNA technology, delivery methods, data science, and automation to create a versatile platform for developing a broad range of medicines.
  • The leadership team, including Dr. Giuseppe Ciaramella, brings extensive experience in drug discovery and biotherapeutics, providing a strategic advantage in the competitive landscape.

Help us improve and share your feedback! Did you find this helpful?